Anti-inflammatory Patents (Class 514/12.2)
-
Patent number: 8658196Abstract: Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).Type: GrantFiled: August 12, 2010Date of Patent: February 25, 2014Assignee: Cook Biotech IncorporatedInventor: Abram D. Janis
-
Patent number: 8653032Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: GrantFiled: November 8, 2010Date of Patent: February 18, 2014Assignees: Korea Food Research Institute, SNU R & DB FoundationInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Patent number: 8648119Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: May 26, 2009Date of Patent: February 11, 2014Assignees: Otonomy, Inc., The Regents of the University of CaliforniaInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
-
Patent number: 8648045Abstract: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.Type: GrantFiled: February 15, 2012Date of Patent: February 11, 2014Assignee: Ben Gurion University of the Negev Research and Development Authority Ltd.Inventors: Varda Shoshan-Barmatz, Salah Abu-Hamad, Laetitia Arzoine, Hilal Zaid
-
Publication number: 20140037712Abstract: A composition for preventing or treating an eye disease includes adiponectin as an active ingredient. Adiponectin as an active ingredient is eventually revealed to show prevention or therapeutic efficacies for eye diseases such as dry eye (syndrome), inflammatory eye disease and side effects due to the use of contact lenses by promoting tear secretion, alleviating ocular surface irregularities, decreasing inflammatory cytokines on the ocular surface and lacrimal gland, and increasing conjunctival goblet cell density. In addition, the composition having eye contact lubrication effects may be used as cleaners or lubricants for preventing non-bacterial inflammation due to wearing contact lenses.Type: ApplicationFiled: November 26, 2012Publication date: February 6, 2014Applicant: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITYInventors: Kyung Chul YOON, Je Moon WOO, Hun Taeg CHUNG
-
Patent number: 8637031Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: October 10, 2012Date of Patent: January 28, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 8637029Abstract: Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.Type: GrantFiled: December 18, 2008Date of Patent: January 28, 2014Assignee: XOMA Technology Ltd.Inventor: Alan M. Solinger
-
Patent number: 8628775Abstract: Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as inflammatory diseases, autoimmune diseases, transplant rejection, and allergic diseases.Type: GrantFiled: September 18, 2009Date of Patent: January 14, 2014Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang
-
Patent number: 8618054Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.Type: GrantFiled: May 5, 2005Date of Patent: December 31, 2013Assignees: Valorisation-Rechereche Société en Commandite, Valorisation HSJ, Société en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
-
Patent number: 8618060Abstract: The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: GrantFiled: February 12, 2007Date of Patent: December 31, 2013Assignee: University of TasmaniaInventors: Vladimir Berezin, Elisabeth Bock, Milena Penkowa
-
Patent number: 8613920Abstract: The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A?. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.Type: GrantFiled: July 27, 2007Date of Patent: December 24, 2013Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLCInventors: Ivan Lieberburg, James Callaway, Michael Grundman
-
Patent number: 8613927Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: February 28, 2012Date of Patent: December 24, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 8614186Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.Type: GrantFiled: May 27, 2010Date of Patent: December 24, 2013Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC.Inventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 8609693Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.Type: GrantFiled: May 27, 2010Date of Patent: December 17, 2013Assignee: GlaxoSmithKline LLCInventors: Connie L. Erickson-Miller, Julian Jenkins
-
Patent number: 8609613Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: July 18, 2012Date of Patent: December 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Patent number: 8586533Abstract: A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.Type: GrantFiled: December 15, 2009Date of Patent: November 19, 2013Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Chung-Hwan Chen
-
Patent number: 8580735Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: GrantFiled: February 5, 2008Date of Patent: November 12, 2013Assignee: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8568730Abstract: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.Type: GrantFiled: April 22, 2010Date of Patent: October 29, 2013Assignee: Indiana University Research & Technology CorporationInventor: David S. Wilkes
-
Patent number: 8563683Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.Type: GrantFiled: July 20, 2007Date of Patent: October 22, 2013Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of GuelphInventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
-
Patent number: 8546331Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.Type: GrantFiled: July 10, 2012Date of Patent: October 1, 2013Assignee: XBiotech, Inc.Inventor: John Simard
-
Patent number: 8535671Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: GrantFiled: September 22, 2011Date of Patent: September 17, 2013Assignee: AlderBio Holdings LLCInventor: Jeffrey T. L. Smith
-
Patent number: 8530420Abstract: A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided.Type: GrantFiled: December 16, 2008Date of Patent: September 10, 2013Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Chung-Hwan Chen
-
Patent number: 8530421Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX(or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a is pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: GrantFiled: August 24, 2010Date of Patent: September 10, 2013Assignee: Supadelixir Inc.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
-
Patent number: 8524862Abstract: The present invention refers to muteins of the C5a anaphylatoxin (C5a) which are C5a receptor antagonists, to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of C5a anaphylatoxin, to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the C5a anaphylatoxin as well as to a pharmaceutical composition comprising a mutein of the C5a anaphylatoxin acting as a C5a receptor antagonists. A mutein of the invention is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated.Type: GrantFiled: March 19, 2002Date of Patent: September 3, 2013Assignee: Cincinnati Children's Hospital Medical CenterInventors: Magnus Otto, Jörg Köhl
-
Patent number: 8524866Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.Type: GrantFiled: November 15, 2006Date of Patent: September 3, 2013Assignee: The Feinstein Institute for Medical ResearchInventors: Lihong Yang, Kevin J. Tracey
-
Patent number: 8518905Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.Type: GrantFiled: May 1, 2012Date of Patent: August 27, 2013Assignee: University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: David J. Hackam, Steven C. Gribar
-
Patent number: 8518903Abstract: The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.Type: GrantFiled: May 13, 2011Date of Patent: August 27, 2013Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventor: David J. Hackam
-
Patent number: 8455437Abstract: Methods for modulating responsiveness to increased oxygen levels in an at-risk subject identifying an at-risk subject; and before exposing the identified at-risk subject to an increased amount of oxygen, administering to the at-risk subject an anti-inflammatory agent wherein the responsiveness of the at-risk subject to said increased amount of oxygen is modulated as compared to the responsiveness of the at-risk subject to said increased amount of oxygen in the absence of said anti-inflammatory.Type: GrantFiled: January 25, 2006Date of Patent: June 4, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Michail V. Sitkovsky, Manfred Thiel
-
Patent number: 8455431Abstract: The present invention is an inhibitor of the trypsin-like ?2/?2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the ?2/?2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.Type: GrantFiled: February 17, 2012Date of Patent: June 4, 2013Assignees: Trustees of Dartmout College, Leiden UniversityInventors: Alexei Kisselev, Dmitry V. Filippov, Herman Overkleeft
-
Publication number: 20130109614Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.Type: ApplicationFiled: June 12, 2012Publication date: May 2, 2013Inventors: Jya-Wei Cheng, Kuo-Chun Huang, Hsi-Tsung Cheng, Hui-Yuan Yu
-
Patent number: 8426366Abstract: Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: GrantFiled: April 29, 2012Date of Patent: April 23, 2013Inventor: Yitzchak Hillman
-
Patent number: 8420089Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: GrantFiled: November 24, 2009Date of Patent: April 16, 2013Assignee: AlderBio Holdings LLCInventor: Jeffrey T. L. Smith
-
Patent number: 8420096Abstract: Disclosed are compositions and methods related to cell-penetrating suppressor of cytokine signaling (SOCS) proteins that inhibit cytokine-induced signaling.Type: GrantFiled: March 4, 2005Date of Patent: April 16, 2013Assignee: Vanderbilt UniversityInventors: Jack J. Hawiger, Daewoong Jo
-
Publication number: 20130079274Abstract: In general, the present invention relates to a new use of lipopeptides or lipoprotein molecules, namely, for treating dysregulated inflammatory diseases. In particular, the present invention relates to pharmaceutical compositions for use in treating dysregulated inflammatory diseases including SIRS, MODS and sepsis. For example, the MALP-2 molecule allows to treat sepsis.Type: ApplicationFiled: July 30, 2010Publication date: March 28, 2013Inventors: Peter Muehlradt, Tanja Barkhausen, Thomas Tschernig
-
Patent number: 8404235Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: GrantFiled: November 25, 2008Date of Patent: March 26, 2013Assignee: Alderbio Holdings LLCInventor: Jeffrey T. L. Smith
-
Publication number: 20130072422Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: March 1, 2011Publication date: March 21, 2013Inventors: Kevin D. Shenk, Francesco Paralati, Mark K. Bennett
-
Patent number: 8389474Abstract: Ischemia-reperfusion (IR) injury involving harvested organs and allograft transplantation may be increased by stimulation of a newly described innate pro-inflammatory immune system (i.e.NALP-3-inflammasome) which can cause secretion of IL-1? and subsequent neutrophilic inflammation. Ischemia and hypoxia can cause metabolic acidosis and development of danger signals known to stimulate IL-1? secretion from the NALP-3 inflammasome. Based on this newly discovered mechanism causing pathobiology in IRI, IL-1? targeted therapy would be capable of improving allograft tolerance, viability of harvested organs and in conditions with compromised arterial blood supply and subsequent reperfusion, such as replants, compartment syndrome, and serious vascular accidents.Type: GrantFiled: July 9, 2010Date of Patent: March 5, 2013Inventor: Alan Anson Wanderer
-
Patent number: 8377882Abstract: Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum. Also disclosed is a kit including a composition or a lyophilisate and instructions for use. A further embodiment of the present invention is method of stabilizing IL-6, an isoform or a fragment thereof, including the steps of mixing IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum.Type: GrantFiled: June 16, 2011Date of Patent: February 19, 2013Assignee: Roche Diagnostics Operations, Inc.Inventor: Christian Schneider
-
Patent number: 8367609Abstract: This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.Type: GrantFiled: January 18, 2007Date of Patent: February 5, 2013Assignee: The General Hospital CorporationInventors: Michael Detmar, Kentaro Kajiya
-
Patent number: 8367605Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Type: GrantFiled: September 26, 2011Date of Patent: February 5, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
-
Patent number: 8362218Abstract: The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.Type: GrantFiled: April 16, 2010Date of Patent: January 29, 2013Assignee: New York University School of MedicineInventor: Chuanju Liu
-
Publication number: 20130012438Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.Type: ApplicationFiled: April 27, 2012Publication date: January 10, 2013Applicant: DYAX CORP.Inventors: Henry Blair, Thomas Beck, Robert Charles Ladner
-
Patent number: 8329657Abstract: Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.Type: GrantFiled: August 11, 2011Date of Patent: December 11, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Mark L. Tykocinski, Marjaneh Razmara
-
Patent number: 8329643Abstract: The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present invention also relates to methods for reducing and/or modulating inflammatory responses by administration of the peptide of the present invention. Furthermore, the present invention relates to the modulation of the expression of cytokines effected as part of an inflammatory response by administration of the peptide of the present invention.Type: GrantFiled: June 24, 2009Date of Patent: December 11, 2012Assignee: Trustees of Boston UniversityInventors: Salomon Amar, Xiaoren Tang
-
Publication number: 20120309674Abstract: The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compounds of formula (2), and to the use thereof as contrast agents for detecting extracellular matrix metalloproteinases.Type: ApplicationFiled: August 26, 2010Publication date: December 6, 2012Applicant: Commissariat A L'Energie Atomique ET Aux Ene AltInventors: Laurent Devel, Fabrice Beau, Bertrand Czarny, Vincent Dive
-
Publication number: 20120308570Abstract: The present invention relates to methods of modulating the level of inducible nitric oxide synthase (iNOS) in a cell which comprises administering to the cell a compound which modulates binding of SPRY domain-containing SOCS box protein (SSB) to iNOS, and/or a compound which modulates SSB activity in the cell. Further provided are methods of treating or preventing disease in a subject by modulating the level of iNOS in a cell, as well as compounds which modulate binding of SSB to iNOS and compounds which modulate SSB activity.Type: ApplicationFiled: May 6, 2010Publication date: December 6, 2012Inventors: Tatiana Kolesnik, Zhihe Kuang, Rowena Sue Lewis, Sandra Elaine Nicholson, Ray Norton
-
Patent number: 8324161Abstract: Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus. Leukotriene B4 polypeptide, the polynucleotide encoding Leukotriene B4 polypeptide, and Leukotriene B4 polypeptide related polypeptides may be used as research reagents and for treatments and diagnostics specific to animal and human diseases.Type: GrantFiled: September 10, 2008Date of Patent: December 4, 2012Assignees: Universite Libre de Bruxelles, Faculte Universitaire des Sciences Agronomiques de GemblouxInventors: Edmond Godfroid, Jérôme Beaufays, Luc Vanhamme, Benoît Adam, Laurence Lins, Sébastien Santini, Robert Brasseur
-
Patent number: 8309088Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 23, 2010Date of Patent: November 13, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20120282285Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: July 16, 2010Publication date: November 8, 2012Applicants: RIGSHOSPITALET, SYDDANSK UNIVERSITET, KØBENHAVNS UNIVERSITETInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20120283182Abstract: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and therefore all peptides shown in the Figures of this application (combined with the HIV-Tat protein transduction, COIV mitochondrial targeting and Flag domains) are included for their efficacies in these conditions.Type: ApplicationFiled: February 21, 2012Publication date: November 8, 2012Inventors: John A. Johnson, Tiffany Tuyen M. Nguyen, Mourad Ogbi